Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

Onyx rejects $10bn takeover bid from Amgen

Says offer is too low, but doesn't rule out a deal

- PMLiVE

FDA clears Amgen’s Xgeva for rare bone condition

US approval provides alternative to surgery for use in giant cell tumour of the bone

- PMLiVE

ASCO: Amgen says viral therapy for melanoma “encouraging”

T-VEC is potential advancement in skin cancer treatment

- PMLiVE

Amgen boosts Japan prospects with Astellas partnership

Companies establish joint venture and plan to co-develop new medicines

UCB and IBM to harness big data for personalised epilepsy care

Joint project could pave the way for therapy area use of IBM's Watson

Amgen and Novartis partner with biotech venture capital firm

Atlas Venture fund aims to create 15 new biotech companies

- PMLiVE

Amgen forms joint venture in China to boost Vectibix

Partners with Zhejiang Beta Pharma on colon cancer drug

- PMLiVE

Steve Arnold joins UCB from Gilead

Appointed managing director for the British and Irish Isles

- PMLiVE

Amgen says viral melanoma therapy clears phase III trial

OncoVex demonstrates durable response in skin cancer patients

- PMLiVE

UCB CEO: Patient info more important than transparency

Roch Doliveux says misinformation is the “worst thing that can happen in healthcare”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links